Amryt, a biopharmaceutical company focused on rare and orphan diseases, is pleased to announce that it has signed an exclusive distribution agreement for Lojuxta® (lomitapide) covering Romania and Bulgaria with Romastru Trading SRL (“Romastru”), a Bucharest-based pharmaceutical services company, part of Pharaon Healthcare Europe, a conglomerate which provides a wide range of services, including medical, marketing research, storage and distribution.
This is the fourth distribution agreement signed by Amryt in the last three months, and it broadens further the Company’s distribution footprint for Lojuxta in Central and Eastern Europe. The Company aims to complete further agreements across its in-licenced territories in Europe, Middle East and Africa as the year progresses.
Lojuxta is a treatment for Homozygous Familial Hypercholesterolemia (“HoFH”), the rare, life-threatening, genetic cholesterol disorder, and Amryt estimates that there are approximately 30 patients with HoFH in Romania and Bulgaria combined.
Dr. Joe Wiley, Chief Executive Officer of Amryt Pharma, said:
“We are pleased to have signed this agreement with Romastru, a long-established pharmaceutical services company based in Bucharest. Romastru’s reach across Romania and Bulgaria means that we can now provide comprehensive access to Lojuxta for adult patients suffering from HoFH in these territories.”
All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned